Analytical Data
-
基因名
SIGLEC14
- Application
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q08ET2
-
表达区间
Gln24~Leu137
-
分子量
20kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SIGLEC14 is a member of the sialic acid-binding immunoglobulin-like lectin (SIGLEC) family, predominantly expressed on the surface of immune cells. Its significance lies in its role in modulating immune responses, particularly in recognizing sialylated glycoconjugates on pathogens and infected cells, which can either enhance or inhibit immune cell activity. Research on SIGLEC14 has gained traction due to its potential implications in various diseases, including infections and autoimmune disorders. Notably, it has been implicated in the immune evasion mechanisms utilized by certain pathogens, as well as in the regulation of inflammation. The study of SIGLEC14 recombinant proteins is critical for understanding its structural properties, ligand binding mechanisms, and functional roles in immune modulation. Furthermore, advances in recombinant protein technology have enabled the production of functional SIGLEC14 proteins, facilitating high-throughput screening and therapeutic applications. Such studies could elucidate the therapeutic potential of targeting SIGLEC14 to enhance protective immune responses or mitigate excessive inflammation, thereby providing new avenues for vaccine development and immunotherapy strategies. Overall, SIGLEC14 research holds promise for translating basic immunological insights into clinical applications, contributing to advances in personalized medicine and the development of novel therapeutic agents.
